|

Adenosine vs Diltiazem for Treatment of SVT in the ED

RECRUITINGPhase 4Sponsored by Anne E. Zepeski
Actively Recruiting
PhasePhase 4
SponsorAnne E. Zepeski
Started2025-08-01
Est. completion2026-07
Eligibility
Age18 Years – 100 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06993038

Summary

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Eligibility

Age: 18 Years – 100 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Adult patients (18 years and older)
2. Diagnosis of acute, stable SVT in the emergency department

Exclusion Criteria:

1. Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting).
2. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome
3. History of heart failure with reduce ejection fraction (HFrEF) (LVEF\</= 40%)
4. Severe bronchoconstrictive lung disease
5. Prior hypersensitivity to study medication
6. Previously enrolled in pilot study
7. Pregnant
8. Incarcerated

Conditions2

Heart DiseaseSupraventricular Tachycardia (SVT)

Locations1 site

University of Iowa Health Care
Iowa City, Iowa, 52242
Anne Zepeski, PhamD651-207-9357anne-zepeski@uiowa.edu

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.